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Abstract
Stroke is a major cause of mortality and long–term disability in the
world. Predictive outcome models in stroke are valuable for personalized
treatment, rehabilitation planning and in controlled clinical trials. In
this paper we design a new model to predict outcome in the short-term,
the putative therapeutic window for several treatments. Our regression-
based model has a parametric form that is designed to address many
challenges common in medical datasets like highly correlated variables
and class imbalance. Empirically our model outperforms the best–known
previous models in predicting short–term outcomes and in inferring the
most effective treatments that improve outcome.
1 Introduction
Stroke is the second–leading cause of death and the leading cause of serious
long–term disability in the world; it is the fifth–leading cause of death in the
USA with an estimated annual economic burden of $34 billion [15]. About
87% of all strokes are ischemic strokes where blood flow to the brain is blocked
[15]. Discovering risk factors, predicting outcome, mortality and complications,
planning patient rehabilitation and treatment are all active areas of research
within both medical and machine learning communities [12, 14, 19].
Stroke impairs many critical neurological functions, causing a broad range
of physical and social disabilities. The final outcome after a stroke can range
from complete recovery to permanent disability and death. Accurate outcome
prediction has several uses: to guide treatment decisions, set prognostic expecta-
tions, plan rehabilitation, and select patients in controlled clinical trials. Many
outcome models have been proposed that differ mainly in the risk factors used
as predictors, for example, [11, 2, 18] that use clinical and imaging variables to
predict outcome at 3–6 months after stroke, and [7, 13, 16] using only a few
clinical variables for predicting outcome and mortality at 3–9 months.
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The modified Rankin scale, shown in table 1, is a quantified measure of
disability and has been widely used to evaluate stroke outcomes [23]. The
validity and reliability of the scale has been extensively studied and attested
[3].
1 No symptoms at all
2 No significant disability despite symptoms; able to
carry out all usual duties and activities
3 Slight disability; unable to carry out all previous ac-
tivities, but able to look after own affairs without as-
sistance
4 Moderate disability; requiring some help, but able to
walk without assistance
5 Moderately severe disability; unable to walk without
assistance and unable to attend to own bodily needs
without assistance
6 Severe disability; bedridden, incontinent and requiring
constant nursing care and attention
7 Dead
Table 1: Modified Rankin Scale [23]
The aim of this work is to design a statistical model that can (1) predict
short–term stroke outcome in a patient and (2) infer the treatments that are
most influential in affecting outcome. Stroke treatment must be tailored to
the individual based on identification of the risk of damage and estimation of
potential recovery [9], and is one of the most important uses of outcome models.
However existing outcome models use only a small number of predictive factors
and are considered to be unreliable for guiding treatments (see [6, 8] for details).
In this study, we model the outcome using 6 past conditions, 3 demographic
variables, 16 clinical variables, 23 treatment variables and the admission Rankin
score (that measures the patient’s initial condition).
Unlike previous outcome models, our model is designed to learn the factors
that affect outcome in the short–term, between admission and discharge, that is
believed to be the therapeutic window for neuroprotective drugs and thrombol-
ysis [24], although our model can be used to predict long–term effects as well.
To our knowledge, no previous work has studied the combined effects of risk
factors and treatment options, for short–term outcome prediction.
1.0.1 Modeling Challenges
The modeling problem can be viewed as follows.
A subject with initial condition cI progresses to a final condition cF . During
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this transition the subject’s state and the factors affecting it are represented
by features Y . The state of the subject before condition cI is represented by
features X. Conditions cI , cF are typically quantified by a discrete, ordinal
scale.
Such problems occur commonly, though not exclusively, in healthcare. E.g.
in this study, cI is quantified by the patient’s Rankin score at hospital admis-
sion, and cF by the Rankin score at discharge, X represents features like past
conditions and Y represents treatments or procedures undertaken during the
hospital stay. Our aim is to build a predictive model for (the value at) cF using
predictors X,Y, cI , while addressing the following challenges.
• High Correlation. When the time elapsed between cI and cF is short, e.g.
between hospital admission and discharge, and if the effects of Y are not
easily discernible, cI and cF are highly correlated. In such cases, using cI
as a predictor of cF (like in a simple Logistic Regression model) results
in it masking the effect of all the variables in Y . This results in trivial
predictions (predicted value of cF equals that of input cI) and makes it
impossible to infer the effects of Y on the final condition.
Note there are no assumptions on the correlation among the predictors
X,Y, cI and techniques like Principal Components Analysis (PCA) may
be applied to obtain uncorrelated features. This still does not solve the
problem of high correlation with the outcome variable, cF .
• Multiple Classes. Each of the states can have multiple levels, e.g. 7 levels
for Rankin score. It is possible to build separate classification models
for each pair (cI , cF ) or for each initial condition cI , but such models
are unable to utilize all the information present in the data, as we show
empirically.
• Data Imbalance. Due to the high correlation present, most of the subjects
begin and end with the same level in cI , cF . Observations with differ-
ent conditions, cI 6= cF , are far fewer in number leading to the classical
problem of imbalance prevalent in many medical datasets [22, 17].
• Small Datasets. Many clinical studies are conducted on small groups of
volunteers and such datasets are typically small. The presence of imbal-
ance, multiple classes, correlations and high dimensional features makes
the modeling task even more challenging on such datasets.
• Missing Data. Medical datasets often contain missing values mainly be-
cause not all measurements/investigations are done for all patients. While
many previous works have addressed missing value imputation for contin-
uous data, few have satisfactorily dealt with discrete data.
1.0.2 Our Contributions
1. We present a new regression–based model for predicting the value of cF
using X,Y, cI . When used for predicting short–term stroke outcome it
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achieves significantly higher accuracy than the best–known previous mod-
els. The parametric form of our model is designed to address the challenges
listed that are prevalent in clinical datasets.
2. Our model allows us to infer the most effective treatments in influenc-
ing outcome and are independently validated by previous clinical studies.
Other competitive models are unable to produce similar clinically justifi-
able inferences.
3. We present a new technique for imputing missing categorical data, that
achieves higher accuracy than state-of-the-art multiple imputation meth-
ods.
2 Our New Model
Let N be the total number of observations in the (training) data. Let XN×L
denote the feature matrix relevant prior to condition cI , we use xk to denote the
L–dimensional feature vector for observation k. Similarly, we use YN×M and
yk, respectively, to denote the feature matrix and M–dimensional feature vector
for observation k, relevant between cI and cF . See table 5 for examples of such
features in our stroke dataset. Let conditions cI , cF be measured on an integral
scale of 1 to K. The K ×K contingency table, Ω, below shows the number of
subjects (in training), ni,j with condition cI = i and condition cF = j, where
i = 1, . . .K; j = 1, . . .K.

Score 1 .. j .. K
1 n1,1 .. n1,j .. n1,K
: .. .. .. .. ..
i ni,1 .. ni,j .. ni,K
: .. .. .. .. ..
K nK,1 .. nK,j .. nK,K

Given the data, the likelihood can be modelled as a multinomial probability
subject to the condition
K∑
j=1
p(i → j|xk, yk) = 1,∀i, k. (ignoring parameter-
independent normalization constants):
L(θ) ∝
N∏
k=1
K∏
i=1
K−1∏
j=1
{p(i→ j|xk, yk)rk,ick,j}{1−
K−1∑
j=1
p(i→ j|xk, yk)}rk,ick,K
rk,i =
{
1, if the kth observation has cI = i (i
th row)
0, otherwise
ck,j =
{
1, if the kth observation has cF = j (j
th column)
0, otherwise
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where p(i→ j|xk, yk) is the probability of a subject with condition cF = j,
given features xk, yk and initial condition cI = i. We propose the following form
for p(i→ j|xk, yk):
p(i→ j|xk, yk) = λi(xk)
α+ λi(xk) +Kij γj(yk)
where:
λi(xk) = exp(β0i +
L∑
l=1
βli xkl), denotes the effects of features xk on the initial
condition cI (i
th row effect). γj(yk) = exp(δ0j +
M∑
m=1
δmj ykm), denotes the
effects of features yk on the final condition cF (j
th column effect).
Kij = C{(j − i)2 + 1}; C and α are constants.
We now justify our choice of this parametric form.
1. The row effects λi(xk) depend only on features relevant before cI while
the column effects γj(yk) depend on features relevant between cI and cF .
2. One of our objectives is to also find which features yk lead to an improve-
ment in the subject’s condition, i.e. cF < cI . Since yk appears only in
the denominator, feature coefficients with the least values (most negative)
will have the maximum impact in improvement.
3. Since the model is purely probabilistic, distributions of these coefficients
can be derived and hence p–values can be computed, to test the signifi-
cance of the features.
4. In small datasets with imbalance, the contingency matrix has higher num-
bers along the diagonals (i.e., most subjects with cI = i remain at cF = i),
with the number of subjects decreasing gradually as we move away from
the diagonal (e.g. a transition from 3, to 2 or 4 is more likely than to 1
or 5). Observing this pattern, we deliberately introduce the term Ki,j ,
which increases the probability value if i is close to j. The constant C
plays the role of weights used in cost–sensitive learning algorithms for im-
balanced data classification [25]. In our case the imbalance is between
diagonal and off–diagonal elements in the contingency table. A higher
value of C increases the weight of off–diagonal elements which helps when
there are very few off–diagonal elements. Strategies similar to those used
in imbalanced data learning can be adopted to choose C, e.g. C can be
chosen to be ndno where nd = Σni,i is the number of diagonal elements and
no = N − nd, is the number of off–diagonal elements.
5. The constant α = 0.001 is added to the denominator to handle model
identifiablity problems. Without the term, multiplying the numerator and
denominator by a constant does not affect the probability but changes the
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coefficient estimates, necessitating constraints on the parameters. Thus,
we add a small constant that ensures unique estimates without affecting
the likelihood.
2.0.3 Advantages of our Approach
• By not taking cI as a feature directly, we overcome the problem of cI being
highly correlated to cF . If cI were to be taken as a feature in a classifier
(like Logistic Regression), it is given the the highest significance and the
rest of the features are ignored (with zero or nearly zero coefficients).
Such a classifier fails to predict well for those subjects whose difference in
condition (cF − cI) is non–zero. Moreover, it fails to infer the effects of yk
on cF .
• Simple predictors that predict differences in outcome (cF − cI) using fea-
tures X,Y do not take into account the differences between varying initial
and final conditions. For example, a subject with initial condition cI = 3
and final condition cF = 1, is different from a subject with cI = 4, cF = 2
and this can affect the predictive performance as seen in our experiments.
• Multiple classifiers can be trained, one for each cI (row). We find that
this approach is severely affected by class imbalance and gives trivial pre-
dictions cF = cI in almost all cases. In contrast, our approach, for a
particular row, takes into account all the observations in the correspond-
ing columns to make the prediction, thus tackling the imbalance and giving
better accuracy, as shown empirically. This is particularly helpful while
learning from small datasets.
• To compute the probability, say p(cI = 2 → cF = 1), we learn from
all the subjects with cF = 1 and from all the subjects with cI = 2, as
opposed to learning from only those subjects with cF = 2 and cI = 1
(which a row-wise classifier will do). Intuitively, all subjects with cF = 1
have some distinguishing characteristics (irrespective of their cI values)
and similarly for all subjects with cI = 2, and our model attempts to
capture this information.
2.0.4 Estimation
Maximum likelihood (ML) estimates of parameters are found using gradient
ascent. We use elastic net regularization(Ref) with regularization constants
λ11, λ12, λ21 and λ22 (λ11 and λ12 are constraints for β ’s while λ21 and λ22 are
constraints for δ ’s). The log likelihood of the data including the regularization
terms is:
l(θ) =
N∑
k=1
K∑
i=1
K−1∑
j=1
rk,ick,j
[
β0i +
L∑
l=1
βli xkl − log{exp(β0i +
L∑
l=1
βli xkl)
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+Kij exp(δ0j +
M∑
m=1
δmj ykm) + α}
]
+
N∑
k=1
K∑
i=1
rk,ick,K
log{1−
K−1∑
j=1
exp(β0i +
L∑
l=1
βli xkl)
α+ exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm)
}
+λ11
K∑
i=1
L∑
l=1
|βli|+ λ12
K∑
i=1
L∑
l=1
βli
2 + λ21
K−1∑
j=1
M∑
m=1
|δmj |+
λ22
K−1∑
j=1
M∑
m=1
δmj
2
ML estimates have to be obtained for the followingK(L+M+2)−(M+1) pa-
rameters θ = {β0i, βli, δ0j , δmj}, i = 1, . . . ,K; j = 1, . . . ,K−1; l = 1, . . . , L;m =
1, . . . ,M (since the probabilities sum to 1 in each row, j iterates over only K−1
entries). We equate the partial derivatives to zero but these partial derivatives
do not have a closed form solution, so we use gradient ascent to solve for the pa-
rameters iteratively. The regularization constants are chosen empirically. The
complete derivation is shown in the appendix.
2.0.5 Computational Complexity
For a K × K contingency table, N observations and feature matrices XN×L
and YN×M , the complexity of estimating all the parameters of our model is
O(tK2N(L+M)) where t is the number of iterations of the gradient ascent.
2.0.6 Outcome Prediction and Feature Importance
To predict the final condition cF of a subject given cI , xk, yk, we compute pˆ(i→
j|xk, yk) from our model (using ML estimates of coefficients), for all K values
of j. The predicted final condition is the value j with the maximum probability.
To evaluate the features that lead to improvement in a subject’s condition,
instead of using the final condition cF , we use an outcome variable ∆, set as
follows: ∆ = 1 if cF − cI > 0, ∆ = −1 if cF − cI < 0 and ∆ = 0 if cF = cI .
The contingency table and model coefficients are recomputed as before. The
interpretation of p(i → ∆|xk, yk) now changes to the probability of a subject’s
condition to change by ∆ (negative indicating improvement, positive indicating
deterioration for the Rankin scale) given the initial condition i and features
X,Y . To find which features lead to an improvement in outcome, i.e. ∆ = −1,
we select the features with the smallest δm∆ (coefficients of ykm) values, with
∆ = −1. Influence of feature interactions in the model can be studied by adding
additional variables (e.g. y1k ∗ y2k) in the yk vector.
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2.0.7 P value Computation
In order to test the significance of a parameter δmj , (m = 1, . . . ,M ; j = 1, . . . ,K)
pertaining to the features Y , we need to test the null hypothesis H0 : δmj = 0
against the alternative hypothesis H1 : δmj 6= 0. Let δ̂mj denote the observed
value and let T = δ̂mj , the ML estimator, denote our test statistic. The p-value
for the two–sided test is 2×min{PH0(T > δ̂mj), PH0(T < δ̂mj)}.
Since the null distribution is not known and we do not have a closed form
expression for T , we use bootstrapping to compute an empirical p–value. We
simulate multiple contingency tables Ωb, b = 1, . . . , 500, and estimate the dis-
tribution of T from Ωb, under the null hypothesis δmj = 0, without changing
the features X,Y . Each table Ωb is initialized to all zeros and then selected
table entries (i, j) (ith row, jth column) are incremented by 1 in the following
way. For each observation with initial condition cI = i, we generate one sample
from a multinomial distribution, with probability pˆ(i→ j|xk, yk, δmj = 0)), and
obtain a value of cF = j, which gives the selection (i, j). In total N incremen-
tations are done, once for each observation in our real dataset. We thus obtain
a bootstrap contingency table Ωb and different final conditions cF on which we
train our model (retaining all other inputs as given) to obtain δ̂bmj , for the b
th
bootstrap, which is a sample from T under the null hypothesis. The empirical
p-value is 2×min{(
500∑
b=1
I
T>δ̂bmj
)/500, (
500∑
b=1
I
T<δ̂bmj
)/500}; Ic = 1 if the condition
c is true, otherwise 0.
2.1 Imputation using Association Score
Let (xi, zi) be the i
th observation with zi denoting the response variable (the
variable to be imputed for feature Z), and xi, the p–dimensional vector of
predictors. As in MICE, we impute zi by sampling from one of the values in
Z−i = {z1, . . . , zi−1, zi+1, . . . , zN}, the subset of the feature values with no miss-
ing values, where N is the total number of observations. For the kth observation
with zk not missing, we define a measure of association Qik =
Cik−Dik
Cik+Dik
where,
Cik =
p∑
i=1
Ixk,j=xi,j , Dik =
p∑
i=1
Ixk,j 6=xi,j ; xi,j denotes the i
th observation for the
jth feature, the sum being over all j for which xk,j and xi,j are not missing
and Ic is an indicator function yielding 1 if the condition c is true, otherwise 0.
Thus, Cik and Dik respectively denote the number of concordant and discordant
pairs between the ith and the kth observations. Qik is similar to the Kendall’s
τ measure of association, with a higher value of Qik indicating stronger associ-
ation. Let Z = {zq} be the list of values with m highest association scores Qiq.
To impute the missing value zi, we select a value at random from the list of Z.
Imputing a single value takes O(Np) time.
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3 Stroke Data Analysis
We retrospectively analyze the data of 275 ischemic stroke patients in the age
group of 45 – 75, admitted to St. John’s Hospital The data includes the variables
listed in table 5 for each patient. Summary statistics for each of the variables are
shown in the appendix. Numerical attributes like investigations are measured
in standard units. Other attributes are suitably encoded as binary or categor-
ical data. For example, addictions, preconditions and treatments are binary
variables indicating presence or absence. Radiology investigations are encoded
into categories indicating normal or abnormal results. Complete details on the
encoding are shown in the appendix. Not all investigations are conducted for
all the patients and the treatment variables differ across patients resulting in a
large number of missing values.
For our dataset, the contingency table, Ω is as follows:

Score 1 2 3 4 5
1 22 0 0 0 0
2 40 29 1 0 0
3 1 44 25 0 2
4 0 0 38 34 2
5 0 0 2 15 20

XN×L
Demographic: Age, Gender, Religion
Time: time between stroke event and treatment start
Addictions: Smoking, Alcohol
Preconditions: Hypertension, Diabetes, Ischemic
Heart Condition, Preceding Fever
cI Initial condition: Rankin Score at admission
YN×M
Investigations: Hemoglobin, Total Counts, Differ-
ential Counts, Platelet, Creatinine, Serum Sodium,
Cholesterol, High Density Lipoprotein (HDL), Low
Density Lipoprotein (LDL), Triglycerides, Admis-
sion Blood Pressure, Electrocardiogram (ECG), Echo,
Doppler
Treatment: Aspirin, Clopidogrel, Atorvastatin, Fi-
nofibrate, Edaravon, Citicoline, Heparin, Dalteparin,
Enoxaparine, Warfarin, Acitrom, t-PA, , Dabigatran,
Anti-hypertensives (ACEI, Beta Channel Blockers, Di-
uretics, ARB), Other drugs (Piracetam, Mannitol, B-
Complex, Pantoprazole, Antibiotics), Physiotherapy
Others: Type of ward, number of days in hospital,
Complication
cF Final Condition: Rankin Score at discharge
Table 2: Stroke Dataset Variables.
3.0.1 Data Preprocessing
Features with values in less than 25% of patients are omitted. We use MICE
[5] to impute all continuous valued features and our association based method
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for imputing categorical features.
We group the Rankin scores into 3 groups: g1 = {1}, g2 = {2, 3} and
g3 = {4, 5, 6, 7} and use these as K = 3 levels. The reduced contingency table
is:

Score g1 g2 g3
g1 22 0 0
g2 41 99 2
g3 0 40 71

3.0.2 Simulated Data
We generate additional synthetic data to evaluate the classifiers on datasets by
varying the total observations N and number of classes (levels in cI , cF ), K.
Datasets with different N are obtained by multiplying the reduced contingency
table above by 2, 10, 15 and 20. Datasets with different K are obtained from
the dataset with N = 5500 by splitting the rows while maintaining the pattern
found in the real data – high diagonal values and off–diagonal values decreasing
with increasing distance from the diagonal. Features X and Y are generated
by sampling from 6–dimensional normal distributions N (µX , I) and N (µY , I)
where µXi = (i − 1 + cI) and µYi = (i + 3 − cF ), i = 1, . . . , 6; I denotes the
identity matrix.
4 Experimental Results
4.1 Accuracy of Imputation Method
To test the performance of our imputation method, we select only those 211
observations having no missing values in the (binary) treatment features and
remove 10% of the values randomly (using these as missing values) from each
feature in X,Y , and apply both MICE and our imputation method. We check
the accuracy of the imputed values which is the proportion of the observations
for which the values are correctly imputed. We repeat the experiment 5 times,
each time with a different random selection of values to be imputed. Table 3
shows the accuracy obtained by MICE, K-Nearest Neighbor (KNN) imputation
[21] and our method which significantly outperforms both the methods.
Method Mean SD
KNN 54.5% 5.16
MICE 59.4% 4.02
Our Method 68.7% 3.86
Table 3: Mean imputation accuracy and standard deviation (SD) over 5 runs of our experi-
ment.
We measure the predictive accuracy of our model and compare it with base-
line models that have been used in previous stroke outcome studies.
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4.1.1 Evaluation Metrics
Accuracy is defined as the proportion of test observations correctly classified.
Overestimate error is defined as the proportion of the misclassified test samples,
out of the total number of samples, for which the predicted outcome, jˆ is greater
than the true outcome, j; i.e. jˆ > j. Similarly the underestimate error measures
the proportion of underestimates, jˆ < j. All results shown are over five–fold
cross validation.
4.1.2 Baselines
As baselines we use classification methods Logistic Regression and Support Vec-
tor Machines in two different ways. First we concatenate X,Y , use them as
features to predict (cF − cI); we denote these classifiers by LR and SVM re-
spectively. Next we train 5 classifiers, one for each value of cI (each row in the
contingency table) and use concatenated features X,Y to predict cF . Given a
test case, based on the admission score (cI), we predict using the corresponding
classifier. We denote these classifiers by LRrow and SVMrow respectively. Our
method is denoted by NEW.
4.1.3 Simulated Data
The performance of all the classifiers on the simulations are shown in figure 1.
We see that the accuracy of NEW is significantly better than all other baselines
and, as expected, the performance improves with more data (increasing N). We
also see that the performance of all classifiers deteriorate as K, the number of
levels cF , cI , increase, making multi–class classification harder. However, our
method maintains its superiority over baselines in all four cases.
4.1.4 Stroke Data
Figure 2 (above) shows the average predictive accuracy of all the classifiers
tested. Logistic Regression (LR) is the best previously used model for predicting
outcome and our model outperforms LR by nearly 19%.
Figure 2 (below) shows the overestimate and underestimate errors of all the
classifiers. Predicting jˆ > j results in overestimating the predicted outcome
and may result in overburdening the patients with unnecessary treatments or
higher dosages. Such false predictions are the least (9.82%) in our method.
Underestimating the outcome, jˆ < j, may result in undermining the predicted
severity of the patient at discharge (or later) and may result in inadequate care.
Our model and SVMrow have the least number of such false predictions (< 7%).
4.1.5 Analysis of Treatment Effects
We illustrate the use of our model in analyzing the effects of treatment in stroke
outcome. We train the model as described earlier that computes p(i→ ∆|xk,yk)
11
Figure 1: Performance on simulated data with fixed K = 3 and increasing N (above) and
fixed N = 5500 and increasing K (below).
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Figure 2: Performance on stroke datset: Mean accuracy over 5–fold cross validation (above);
Overestimate and underestimate errors (below).
where ∆ indicating improvement or deterioration is used as the outcome vari-
able.
Treatment Coefficient P–Value
Piracetam -4.08 0.002
Strocit -3.89 0.007
Physiotherapy -3.61 0.009
Fragmin -3.14 0.013
Warfarin - 2.29 0.026
Clexane -1.67 0.031
Acitrom -1.19 0.037
Heparin -0.76 0.045
Table 4: Treatments with highest impact in improving outcome.
Table 11 shows the treatment variables with the smallest coefficients in our
model along with their p–values. These treatments have been independently
shown to be effective in improving stroke outcome in other studies [4, 1, 10, 20],
which provides additional validation for our model.
The Logistic Regression model (LR) is the only other baseline that can be
used to infer treatment effects. It is also the model that has been used in
previous stroke outcome studies. LR gives Edaravone and Pantoprazole as the
only significant factors with coefficients (pvalues) 0.36 (0.05) and 0.42 (0.007).
While Edaravone has been found to improve outcome, Pantoprazole is given
to inhibit gastric acid secretion, and is unrelated to stroke outcome. Thus LR
is unable to identify all the significant factors and also erroneously shows an
13
unrelated treatment as significant.
5 Conclusion
We develop a new model for predicting stroke outcome that addresses several
challenges common in medical datasets like class imbalance and highly corre-
lated variables and also design a new imputation strategy for discrete data.
Our model is found to be more effective than the best–known previous mod-
els in predicting short–term outcome and inferring clinically justified treatment
effects.
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A Maximum Likelihood Parameter Estimation
The log likelihood of the data including the regularization terms is given by:
l(θ) =
N∑
k=1
K∑
i=1
K−1∑
j=1
rk,ick,j
[
β0i+
L∑
l=1
βli xkl−log{exp(β0i+
L∑
l=1
βli xkl)+Kij exp(δ0j+
M∑
m=1
δmj ykm)+α}
]
+
N∑
k=1
K∑
i=1
rk,ick,K log{1−
K−1∑
j=1
exp(β0i +
L∑
l=1
βli xkl)
α+ exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm)
}
+λ11
K∑
i=1
L∑
l=1
|βli|+ λ12
K∑
i=1
L∑
l=1
βli
2 + λ21
K−1∑
j=1
M∑
m=1
|δmj |+
λ22
K−1∑
j=1
M∑
m=1
δmj
2
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In order to estimate the ML estimates of the parameters θ = (β0i, βli, δ0j , δmj),
we need to equate the following partial derivatives to zero:
∂l(θ)
∂β0i
=
N∑
k=1
K−1∑
j=1
rk,i
[
1−
exp(β0i +
L∑
l=1
βli xkl)
exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm) + α
]
[
ck,j−ck,K
1
1−
K−1∑
j=1
exp(β0i+
L∑
l=1
βli xkl)
α+exp(β0i+
L∑
l=1
βli xkl)+Kij exp(δ0j+
M∑
m=1
δmj ykm)
×
exp(β0i +
L∑
l=1
βli xkl)
α+ exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm)
]
∂l(θ)
∂βli
=
N∑
k=1
K−1∑
j=1
rk,i xkl
[
1−
exp(β0i +
L∑
l=1
βli xkl)
exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm) + α
]
[
ck,j−ck,K
1
1−
K−1∑
j=1
exp(β0i+
L∑
l=1
βli xkl)
α+exp(β0i+
L∑
l=1
βli xkl)+Kij exp(δ0j+
M∑
m=1
δmj ykm)
×
exp(β0i +
L∑
l=1
βli xkl)
α+ exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm)
]
+λ11sign(βli) + 2λ12βli
∂l(θ)
∂γ0j
=
N∑
k=1
K∑
i=1
rk,i
[ Kij exp(δ0j + M∑
m=1
δmj ykm)
exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm) + α
]
[
ck,K
1
1−
K−1∑
j=1
exp(β0i+
L∑
l=1
βli xkl)
α+exp(β0i+
L∑
l=1
βli xkl)+Kij exp(δ0j+
M∑
m=1
δmj ykm)
×
exp(β0i +
L∑
l=1
βli xkl)
α+ exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm)
− ck,j
]
∂l(θ)
∂γmj
=
N∑
k=1
K∑
i=1
rk,i
[ ykmKij exp(δ0j + M∑
m=1
δmj ykm)
exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm) + α
]
[
ck,K
1
1−
K−1∑
j=1
exp(β0i+
L∑
l=1
βli xkl)
α+exp(β0i+
L∑
l=1
βli xkl)+Kij exp(δ0j+
M∑
m=1
δmj ykm)
×
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exp(β0i +
L∑
l=1
βli xkl)
α+ exp(β0i +
L∑
l=1
βli xkl) +Kij exp(δ0j +
M∑
m=1
δmj ykm)
− ck,j
]
+λ21sign(δmj) + 2λ22δmj
These partial derivatives do not have a closed form solution, so we use the gradient ascent
method to solve for the parameters iteratively, the recursion relation at the tth iteration given
by:
θ(t) = θ(t−1) + η∇l(θ(t−1))
where η is the step size, and ∇l(θ(t−1) =
(
∂l(θ(t−1))
∂β0i
,
∂l(θ(t−1))
∂βli
,
∂l(θ(t−1))
∂γ0j
,
∂l(θ(t−1))
∂γmj
)
.
The iterations are continued till convergence,the convergence criterion being:
max(|θ(t) − θ(t−1)|) < 0.0001
B Stroke Data
We retrospectively analyzed the data of 275 stroke patients admitted to a local hospital1.
Only ischemic stroke patients are considered. The age group is restricted to 45 – 75. Patients
suffering from cancer or severe liver/kidney disease, patients in critical care and moribund or
comatose patients are excluded from the study.
The data includes the variables listed in table 5 for each patient. Summary statistics
for each of the variables are shown in tables in the following sections. These tables also
describe the datatype and the encoding used for categorical variable. Not all investigations
are conducted for all the patients and the treatment variables differ across patients. Hence
the data contains a large number of missing values. The number of missing values for each
variable is also shown in the tables below.
1name undisclosed to preserve anonymity in blind submission
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XN×L
Demographic Age, Gender, Religion
Time Dates of event, start of treatment,
admission, discharge
Addictions Smoking, Alcohol
Preconditions Hypertension, Diabetes, Ischemic
Heart Condition, Preceding Fever
cI Initial condition Rankin Score at admission
YN×M
Investigations Hemoglobin, Total Counts, Dif-
ferential Counts, Platelet, Cre-
atinine, Serum Sodium, Choles-
terol, High Density Lipoprotein
(HDL), Low Density Lipopro-
tein (LDL), Triglycerides, Admis-
sion Blood Pressure, Electrocar-
diogram (ECG), Echo, Doppler
Treatment Aspirin, Clopidogrel, Atorvastatin,
Finofibrate, Edaravon, Citicoline,
Heparin, Dalteparin, Enoxaparine,
Warfarin, Acitrom, t-PA, , Dabi-
gatran, Anti-hypertensives (ACEI,
Beta Channel Blockers, Diuretics,
ARB), Other drugs (Piracetam,
Mannitol, B-Complex, Pantopra-
zole, Antibiotics), Physiotherapy
Others Type of ward, Complication
cF Final Condition Rankin Score at discharge
Table 5: Stroke Dataset Variables.
For our dataset, the contingency table, Ω is as follows. The row headers are the values of
cI , the initial condition at admission, and the column headers are the values of cF , the final
condition at discharge, both measured by the Rankin scale. The (i, j)th entry is the number
of patients with cI = i, cF = j.

Score 1 2 3 4 5
1 22 0 0 0 0
2 40 29 1 0 0
3 1 44 25 0 2
4 0 0 38 34 2
5 0 0 2 15 20

B.1 Variables in XN×L
These variables include demographic variables, and variables indicating addictions and pre-
conditions. All these are relevant prior to admission when the initial condition cI is measured.
Name Categorical NA? Summary Statistics
Age N N Min: 45 Med: 58 Mean: 58.32 Max: 75 SD: 8.61
Gender Y N Male: 169, Female: 106
Religion Y N R1: 209, R2: 41, R3: 25, R4: 4, R5: 5, Others: 6
Table 6: Summary Statistics of Demographic Variables. Ri, i = 1, . . . , 5 are
five different religions; Y: Yes, N: No; Min: Minimum, Max: Maximum, SD:
Standard Deviation, Med: Median; NA?: Are there missing values?.
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Name Categorical NA? Count Statistics
Smoking Y N Smokers: 81 Non–smokers: 194
Alcohol Y N Regular: 65 Not regular: 210
Table 7: Summary Statistics of Addiction Variables. Y: Yes, N: No; NA?: Are
there missing values?.
Name Categorical NA? Summary Statistics
Hypertension Y Y: 3 Yes: 149 No: 123
Diabetes Y Y: 1 Yes: 88 No: 186
Ischemic Heart Condition Y N Yes: 31 No: 244
Days of preceding fever N Y: 13 Min: 0, Med: 0, Mean: 0.3, Max: 20, SD: 1.95
Table 8: Summary Statistics of Precondition Variables. Y: Yes, N: No; Min:
Minimum, Max: Maximum, SD: Standard Deviation, Med: Median; NA?: Are
there missing values, if yes, how many?
B.2 Variables in YN×M
These variables include values of various clinical investigations and treatments given between
admission and discharge, i.e. between the initial condition cI and final condition cF measured
by the Rankin scale.
Name Units NA? Min 1st Q Med Mean 3rd Q Max SD
Hemoglobin g/dl Y:5 5.6 11.9 13.4 13.33 14.9 20.6 2.279
Total Counts /ul Y:4 948 7680 9440 10090 11400 70000 4986.96
Neutrophils % Y:16 0 62 69 69.8 78.5 95 12.682
Lymphocytes % Y:16 0 16 24 23.31 30 52.6 9.788
Eosinophils % Y:64 0 1 2 3.749 4.75 61 5.764
Platelet count lakh/ul Y:31 0 1.93 2.3 3.522 2.8 261 16.582
Creatinine mg/dl Y:21 0.1 0.8 1 1.038 1.1 7.1 0.525
Serum Sodium mEq/L Y:60 118 133 135 135.4 137 150 3.811
Total Cholesterol mg/dl Y:37 1.8 143 180 176.4 207 379 47.284
HDL mg/dl Y:35 3 27.75 34 36.19 42 182 15.562
LDL mg/dl Y:35 22 91 118 119.3 141.2 902 63.144
Triglycerides mg/dl Y:38 27 85 123 141 180 584 79.671
Systolic BP mmHg Y:10 90 130 150 149.2 170 230 26.848
Diastolic BP mmHg Y:10 30 80 90 89.34 100 140 14.308
Echo EF % Y:38 0 60 67 64.07 70 90 11.626
Table 9: Summary Statistics of Investigation Variables. Y: Yes, N: No; Min:
Minimum, Med: Median, Max: Maximum, SD: Standard Deviation, 1st Q: first
quartile, 3rd Q: third quartile; NA?: Are there missing values, if yes, how many?
20
Name Normal Abnormal NA?
Doppler 66 152 57
ECG 126 130 19
Echo 53 194 28
Table 10: Summary Statistics of Radiology Variables; encoded as binary based
on findings by consultant doctor. NA?: Are there missing values, if yes, how
many?
Name Prescribed Not Prescribed NA?
Edaravone 80 190 5
Clopidogrel 153 119 3
Citicoline 33 242 0
Heparin 258 15 2
Warfarin 218 53 4
t-PA 268 6 1
ACEI 196 79 0
Beta Channel Blocker 220 55 0
Diuretics 240 26 9
ARB 238 30 7
Piracetam 238 34 3
B. Complex 191 84 0
Met/Glyco 197 76 2
Insulin 196 79 0
Pantoprazole 145 129 1
Physiotherapy 200 73 2
Antibiotics 197 76 2
Finofibrate 264 3 8
Acitrom 270 5 0
Table 11: Summary Statistics of Treatment Variables; encoded as binary based
on prescriptions of consultant doctor. NA?: Are there missing values, if yes,
how many?
Name Units NA? Min 1st Q Med Mean 3rd Q Max SD
Aspirin mg N 1 2 2 3.105 5 10 1.771
Atorvastatin mg N 0 40 40 37.98 40 80 12.915
Dalteparine units N 0 0 0 1973 5000 5000 2188.849
Enoxaparine ml N 0 0 0 0.04364 0 0.6 0.144
Table 12: Summary Statistics of Treatment Variables where dosages were used
in data; 0 indicates not prescribed and nonzero value is the dosage prescribed.
Y: Yes, N: No; Min: Minimum, Med: Median, Max: Maximum, SD: Standard
Deviation, 1st Q: first quartile, 3rd Q: third quartile; NA?: Are there missing
values, if yes, how many?
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B.3 Univariate Analysis
B.3.1 ANOVA
Univariate One Way Analysis of Variance(ANOVA) is performed on each predictor variable
with the Rankin Score at Discharge denoting the groups. The test shows how each of the
variables varies between the groups(i.e high between-group variance and low within-group
variance). Table 13 shows the p-values corresponding to testing of hypothesis H0 : the
variable does not vary across groups , against H1 : The variable varies across the groups.
The variables are arranged in increasing order of p-value ; the null hypothesis is accepted
with 5% level of significance if p-value > 0.05.
B.3.2 Univariate Logistic Regression
Univariate Logistic Regression is performed on each variable by taking the Rankin Score
at Discharge as the response and the variable as the predictor. Table 14 lists the residual
deviances for each variable in increasing order (lower the value, higher is the association
between and the predictor and response). The lowest value of 446.57 for Rankin score at
admission shows the high correlation with outcome at discharge.
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Variables p-value Status
Stay in hospital(Days) 0 Reject
NEUTROPHILS 0 Reject
LYMPHOCYTES 0 Reject
Piracetam 0 Reject
Physiotherapy 0 Reject
Complication 0 Reject
Rankin Score at Admission 0 Reject
Antibiotics 0.001 Reject
Heparin 0.002 Reject
TC 0.005 Reject
Doppler 0.009 Reject
Platelet 0.019 Reject
Cholesterol 0.02 Reject
LDL 0.025 Reject
Diastolic 0.038 Reject
Systolic 0.045 Reject
Warfarin 0.048 Reject
Time between event and Treatment(Days) 0.075 Accept
Serum Na. 0.115 Accept
Dalteparine 0.116 Accept
Ward 0.128 Accept
Aspirin 0.164 Accept
Pantoprazole 0.165 Accept
Preceding fever 0.216 Accept
EOSINOPHILS 0.241 Accept
Hypertension 0.249 Accept
Creatinine 0.283 Accept
Beta Channel Blocker 0.314 Accept
Religion 0.317 Accept
Citicoline 0.325 Accept
Alcohol abuse 0.337 Accept
Atorvastatin 0.357 Accept
Enoxaparine 0.386 Accept
Acitrom 0.394 Accept
ARB 0.424 Accept
Gender 0.428 Accept
EF 0.431 Accept
B Complex 0.457 Accept
Isch Heart Condition 0.548 Accept
Edaravone 0.561 Accept
Clopidogrel 0.567 Accept
Met/Glyco 0.57 Accept
Smoking 0.571 Accept
Triglycerides 0.573 Accept
Echo 0.578 Accept
Insulin 0.587 Accept
Diabetes 0.591 Accept
HDL 0.618 Accept
ECG 0.691 Accept
Finofibrate 0.708 Accept
ACEI 0.736 Accept
Age 0.867 Accept
Diuretics 0.888 Accept
t.PA 0.915 Accept
Hb 0.922 Accept
Table 13: P values from ANOVA
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Variables Residual Deviance
Rankin Score at Admission 446.57
Physiotherapy 852.09
LYMPHOCYTES 862.52
Stay in hospital (Days) 863.60
Complication 863.77
NEUTROPHILS 867.11
Piracetam 868.38
Antibiotics 871.02
Cholesterol 874.58
Gender 874.89
Heparin 875.16
Diuretics 875.53
LDL 875.73
TC 876.00
Diastolic 876.06
Doppler 876.36
Diabetes 878.26
Platelet 879.01
Time between event and treatment (Days) 879.22
Systolic 879.29
EOSINOPHILS 879.45
Serum Na. 880.12
ARB 880.29
Insulin 880.32
Smoking 881.13
Religion 881.14
Finofibrate 881.37
Isch. Heart Condition 882.06
HDL 882.10
Warfarin 882.57
Hb 882.66
Pantoprazole 882.73
Acitrom 883.16
Dalteparine 883.25
Aspirin 883.85
Ward 883.97
Met/Glyco 884.27
Creatinine 884.28
Clopidogrel 884.38
Triglycerides 884.40
Citicoline 884.52
Enoxaparine 884.69
EF 884.82
Atorvastatin 884.98
Alcohol.abuse 885.06
ACEI 885.29
t.PA 885.81
Preceding fever 885.87
Age 886.07
Edaravone 886.66
Beta Channel Blocker 886.80
Hypertension 887.04
Echo 887.14
B. Complex 887.28
ECG 887.31
Table 14: Residual Deviance from Univariate Logistic Regression
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C Simulated Data
We test our model on 4 sets of synthetic data where the contingency tables are simulated from
our dataset by multiplying each element of the reduced contingency matrix from the stroke
dataset by 2,10,15 and 20. 
Score g1 g2 g3
g1 22 0 0
g2 41 99 2
g3 0 40 71

We generate xk and yk by simulating respectively from 6-dimensional normal distributions
N (µXi, I) and N (µY j , I); where µXi =

i
i+ 1
i+ 2
i+ 3
i+ 4
i+ 5
 , µY j =

4− j
5− j
6− j
7− j
8− j
9− j
 and I denotes the identity
matrix. i and j respectively are the values of cI (row) and cF (column).
• Simulation 1
Contingency Table :

Score g1 g2 g3
g1 44 0 0
g2 82 198 4
g3 0 80 142

Results:
Method Mean Accuracy SD
LRrow 72.3% 2.45
SVMrow 71.5% 2.89
LR 73.1% 2.54
SVM 73.5% 2.27
NEW 77.9% 3.1
Table 15: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data 1
• Simulation 2
Contingency Table :

Score g1 g2 g3
g1 220 0 0
g2 410 990 20
g3 0 400 710

Results:
• Simulation 3
Contingency Table :

Score g1 g2 g3
g1 330 0 0
g2 615 1485 30
g3 0 600 1065

Results:
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Method Mean Accuracy SD
LRrow 77.4% 2.15
SVMrow 77.7% 2.66
LR 79% 2.46
SVM 78.8% 2.80
NEW 84.3% 2.99
Table 16: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data 2
Method Mean Accuracy SD
LRrow 79.8% 1.97
SVMrow 80.6% 2.16
LR 82.4% 2.38
SVM 81.7% 2.84
NEW 91.2% 3.26
Table 17: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data 3
• Simulation 4
Contingency Table :

Score g1 g2 g3
g1 440 0 0
g2 820 1980 40
g3 0 800 1420

Results:
Method Mean Accuracy SD
LRrow 83.0% 2.11
SVMrow 82.4% 1.70
LR 85.1% 2.54
SVM 85.2% 2.41
NEW 92.5% 2.45
Table 18: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data 4
C.0.3 Simulation for varying K with N=5500
• K = 3
Contingency Table :

Score g1 g2 g3
g1 440 0 0
g2 820 1980 40
g3 0 800 1420

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Results :
Method Mean Accuracy SD
LRrow 83.0% 2.11
SVMrow 82.4% 1.70
LR 85.1% 2.54
SVM 85.2% 2.41
NEW 92.5% 2.45
Table 19: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data for K=3
• K = 4
Contingency Table :

Score g1 g2 g3 g4
g1 270 170 0 0
g2 300 990 90 40
g3 230 300 790 100
g4 0 300 720 1200

Results :
Method Mean Accuracy SD
LRrow 79.8% 2.8
SVMrow 80.1% 1.94
LR 85% 2.67
SVM 82.8% 2.34
NEW 90.02% 2.78
Table 20: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data for K=4
• K = 5
Contingency Table :

Score g1 g2 g3 g4 g5
g1 270 110 60 0 0
g2 100 580 110 50 20
g3 80 200 420 50 10
g4 70 150 260 740 200
g5 0 200 320 500 1000

Results :
• K = 6
Contingency Table :

Score g1 g2 g3 g4 g5 g6
g1 300 100 70 30 0 0
g2 120 480 150 80 20 10
g3 80 150 370 100 50 10
g4 70 150 200 740 160 100
g5 30 70 110 200 500 100
g6 0 25 60 150 225 670

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Method Mean Accuracy SD
LRrow 77.9% 2.67
SVMrow 77.5% 2.36
LR 83.8% 2.76
SVM 80.6% 2.72
NEW 87.2% 3.23
Table 21: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data for K=5
Results :
Method Mean Accuracy SD
LRrow 74.3% 2.83
SVMrow 73% 2.7
LR 79.9% 2.99
SVM 76.2% 3.21
NEW 85.9% 3.10
Table 22: Average accuracy and standard deviation (SD) over five–fold cross
validation on simulated data for K=6
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